Safety Study of Oral Sodium Phenylbutyrate in Subjects With ALS (Amyotrophic Lateral Sclerosis)
Safety and Dose Escalating Study of Oral Sodium Phenylbutyrate in Subjects With Amyotrophic Lateral Sclerosis
Sponsor: Muscular Dystrophy Association
A PHASE1/PHASE2 clinical study on Amyotrophic Lateral Sclerosis, this trial is completed. The trial is conducted by Muscular Dystrophy Association and has accumulated 7 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Aug 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Completed PHASE1_PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1_PHASE2
First recorded
Apr 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Muscular Dystrophy Association
- US Department of Veterans Affairs
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Baltimore, United States
- • Bedford, United States
- • Boston, United States
- • Cincinnati, United States
- • Durham, United States
- • Houston, United States
- • Iowa City, United States
- • Lexington, United States
- • Pittsburgh, United States
- • Syracuse, United States